Comment from Flagship Pioneering

Summary: Flagship Pioneering, a venture creation and innovation firm, supports the FDA's proposed Expedited Investigational New Drug (IND) Pilot Program to modernize the U.S. system and remain globally competitive. They advocate for specific improvements, including funding for Qualified Research Institutions (QRIs), modular review processes, and alignment with international models like Australia's clinical trial notification pathway.